Development and evaluation of an ELISA for quantification of human alpha-1-proteinase inhibitor in complex biological mixtures

Biologicals

Volumn 35, Issue 4, 2007, Pages 285-295

  Karnaukhova, Elena ^a   Golding, Basil ^a   Ophir, Yakir ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Alpha 1 proteinase inhibitor; Antitrypsin; ELISA; Evaluation

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL PRODUCT; LEUKOCYTE ELASTASE; POLYCLONAL ANTIBODY; RECOMBINANT ALPHA 1 PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ACCURACY; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANALYTIC METHOD; ARTICLE; ASPERGILLUS NIGER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG POTENCY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EVALUATION; FATALITY; FERMENTATION; HUMAN; LUNG EMPHYSEMA; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; STANDARDIZATION;

ALPHA 1-ANTITRYPSIN; ASPERGILLUS NIGER; BIOPOLYMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FERMENTATION; HEAT; HUMANS; QUALITY CONTROL; RECOMBINANT PROTEINS; REFERENCE STANDARDS;

EID: 35248873491     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2006.11.002     Document Type: Article

References (17)

1. Brantly M.L., Wittes J.T., Vogelmeier C.F., Hubbard R.C., Fells G.A., and Crystal R.G. Use of highly purified alpha-1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest 100 3 (1991) 703-708
2. 1-antitrypsin gene and its deficiency states. Trends Genet 5 (1989) 411-417
3. Crystal R.G. Alpha 1-antitrypsin deficiency. In: Crystal R. (Ed) (1996), Marcel Dekker, Inc. 449
4. 1-antitrypsin deficiency and the serpinopathies. Clin Med JRCPL 5 (2005) 249-257
5. Cowden D.I., Fisher G.E., and Weeks R.L. A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products. Curr Med Res Opin 21 6 (2005) 877-883
6. Talamo R.C., Bruce R.M., Langley C.E., Berninger R.W., Pierce J.A., Bryant L.J., et al. Alpha-1-antitrypsin laboratory manual (1978), Department of Health Education and Welfare pub. No. NIH 78-1420, National Institute of Health, Bethesda, MD p. 1-129
7. 1-antitrypsin phenotypes. Chest 100 (1991) 703-708
8. Karnaukhova E., Ophir Y., and Golding B. Recombinant alpha-1 proteinase inhibitor towards therapeutic use. Amino Acids 30 (2006) 317-332
9. Voller A., Bartlett A., and Bidwell D.E. Enzyme immunoassays with special reference to ELISA techniques. J Clin Pathol 31 (1978) 507-520
10. ICH. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Text on validation of analytical procedures; 1994. pp. 1-5.
11. ICH. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Validation of analytical procedures: methodology; 1996. pp. 1-8.
12. US FDA Guidances: U.S. Food and Drug Administration. Guidance for industry: manufacturing, processing, or holding active pharmaceutical ingredients (March 1998)
13. US FDA Guidances: U.S. Food and Drug Administration. Guidelines on general principles of process validation (May 1987)
14. The United States Pharmacopeia. USP 26. General information 1225O, validation of compendial methods; 2003. pp. 2439-42.
15. Edelhoch H. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6 (1967) 1948-1954
16. Karnaukhova E, Ophir Y, Golding B, Shrake A. Recombinant human alpha-1-proteinase inhibitor: glycosylation, stability and biological activity. Abstract of 10th FDA Science Forum: The critical path from concept to consumer. B-18, p. 47. Washington DC, May 18-19, 2004.
17. Karnaukhova E., Ophir Y., Trinh L., Shrake A., Golding B., Punt P.J., et al. Recombinant human alpha-1-proteinase inhibitor. Expression in Aspergillus niger. Amino Acids 29 1 (2005) 51